In the biologic era, several studies reported an elevated rate of malignancy in JIA patient treated with TNF-α inhibitors and in 2009 the US Food and Drug Administration (FDA) placed a black box warning for these drugs, as result of the identification of 48 malignancies cases occurring in children exposed to anti TNF-α biologic drugs [104]. Here, TNF is linked to juvenile idiopathic arthritis.